

TECHNICAL BRIEF

(ARCHIVED) COVID-19 Vaccines with World Health Organization (WHO) Emergency Use Listing (EUL)

Published: July 2021

Archived: May 2022

ARCHIVED DOCUMENT

This archived content is being made available for historical research and reference purposes only. PHO is no longer updating this content and it may not reflect current guidance.

Introduction

This table provides a summary of COVID-19 vaccines that have been assessed and listed for [emergency use listing \(EUL\) by the World Health Organization \(WHO\)](#). WHO EUL is a risk-based procedure for assessing and listing unlicensed vaccines, with a goal of expediting the availability of vaccine products during public health emergencies, with additional recommendations on their use provided by the WHO's [Strategic Advisory Group of Experts on Immunization \(SAGE\)](#).¹ This document is intended to support health care providers and public health partners to perform COVID-19 immunization record assessments for vaccines received outside Canada, to counsel patients on recommendations for additional dose(s) of Health Canada authorized vaccines for those with series initiated outside Ontario, and to support standardized data entry in COVaxON. This document is based on [WHO Guidance from July 15, 2021](#) and will be updated, as new products are reviewed and receive EUL by the WHO.

For more information on individuals receiving COVID-19 vaccines outside Ontario see the Ministry of Health's [Guidance for Individuals Vaccinated outside of Ontario/Canada](#).

Table 1: COVID-19 Vaccines with World Health Organization (WHO) Emergency Use Listing (EUL)*

Manufacturer (WHO EUL holder) ^a	Date Approved ^b	Vaccine Generic Name	Vaccine Trade Name(s)**	Vaccine Platform	Doses in Schedule	Interval Between Doses: Authorized ^c	Interval Between Doses: Minimum ^d	COVaxON: Agent Name	COVaxON: Trade Name
Pfizer – BioNTech	Jan-8-2021	BNT 162b2	<i>Pfizer-BioNTech COVID-19 Vaccine</i> <i>Comirnaty</i> <i>Tozinameran</i>	mRNA	2	21 days	19 days	COVID-19 mRNA	PFIZER-BIONTECH COVID-19 VACCINE mRNA
Moderna	Jan-25-2021	mRNA-1273	<i>Moderna COVID-19 Vaccine</i> <i>Spikevax</i>	mRNA	2	28 days	21 days	COVID-19 mRNA	MODERNA COVID-19 mRNA-1273
AstraZeneca/Oxford University	Feb-10-2021	ChAdOx1-S [AZD1222]	<i>AstraZeneca COVID-19 Vaccine</i> <i>Vaxzevria</i>	Viral vector (non-replicating)	2	4 to 12 weeks	28 days	COVID-19 non-replicating vector vaccine	ASTRAZENECA COVID-19 VACCINE
Serum Institute of India (SII)	Feb-15-2021	ChAdOx1-S []	<i>COVISHIELD COVID-19 Vaccine</i> <i>COVISHIELD</i>	Viral vector (non-replicating)	2	4 to 12 weeks	28 days	COVID-19 non-replicating vector vaccine	COVID-19 COVISHIELD
Janssen (Johnson & Johnson)	Mar-17-2021	Ad26.COVS.S	<i>Janssen Ad26.COVS.S COVID-19 vaccine</i> <i>Janssen COVID-19 vaccine</i>	Viral vector (non-replicating)	1	N/A	N/A	COVID-19 non-replicating vector vaccine	JANSSEN COVID-19 VACCINE

Manufacturer (WHO EUL holder) ^a	Date Approved ^b	Vaccine Generic Name	Vaccine Trade Name(s)**	Vaccine Platform	Doses in Schedule	Interval Between Doses: Authorized ^c	Interval Between Doses: Minimum ^d	COVaxON: Agent Name	COVaxON: Trade Name
Sinopharm ^e	May-7-2021	COVID-19 vaccine BIBP	<i>Sinopharm COVID-19 Vaccine BIBP-CorV</i> <i>BBIBP – CorV</i> <i>Covilo</i>	Inactivated virus	2	21-28 days	N/A	COVID-19 inactivated virus unspecified	SINOPHARM-BIBP COVID-19 Vaccine
Sinovac	Jun-1-2021	Ad5-nCoV Sinovac-CoronaVac	<i>Sinovac COVID-19 Vaccine CoronaVac</i> <i>Sinovac PiCoVacc</i>	Inactivated virus	2	14-28 days	N/A	COVID-19 inactivated virus unspecified	CoronaVac COVID-19 Vaccine

^a The name of vaccine manufacturer who has applied for and received emergency use listing (EUL) from the World Health Organization (WHO).¹

^b The date the vaccine product obtained emergency use listing (EUL) from the World Health Organization (WHO).¹

^c The interval between doses in the vaccine series as authorized by the vaccine manufacturer.

^d For COVID-19 vaccines authorized for use by Health Canada, refers to the minimum interval between doses in a vaccine series as recommended by Canada's [National Advisory Committee on Immunization \(NACI\)](#).³

^e Sinopharm (Beijing, BIBP-CorV) has been authorized by the WHO as an EUL vaccine, but Sinopharm (Wuhan, WIBP-CoV) has only been authorized for use in China. COVID-19 Vaccine (Vero cell) is being used on some COVID-19 immunizations records to refer to both Sinopharm and Sinovac.

* For a list of authorized vaccines by country, please see COVID 19 Vaccine Tracker: [Trials & Approved Vaccines by Country](#).⁵

** Trade names vary by country/region; this list includes all currently known trade names.

*** For update to date information on vaccine efficacy and effectiveness, please see [National Advisory Committee on Immunization \(NACI\) Recommendations on the Use of COVID-19 Vaccines](#)³ and WHO's [Strategic Advisory Group of Experts on Immunization \(SAGE\) COVID-19 Vaccine Technical Documents](#).⁴

References

1. World Health Organization (WHO). Regulation and pre-qualification: emergency use listing [Internet]. Geneva: World Health Organization; 2021 [cited 2021 Jul 23]. Available from: <https://www.who.int/teams/regulation-prequalification/eul/>
2. World Health Organization (WHO). COVID-19 vaccine tracker and landscape [Internet]. Geneva: World Health Organization; 2021 [updated on 2021 Jul 23; cited on 2021 Jul 23]. Available from: <https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines>
3. National Advisory Committee on Immunization (NACI); Public Health Agency of Canada. Recommendations on the use of COVID-19 vaccines [Internet]. Ottawa, ON: Government of Canada; 2021 [cited 2021 Jul 22]. Available from: <https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/recommendations-use-covid-19-vaccines-en.pdf>
4. Strategic Advisory Group of Experts on Immunization (SAGE); World Health Organization (WHO). COVID-19 vaccines technical documents. [Internet]. Geneva: World Health Organization; 2021 [cited on 2021 Jul 23]. Available from: <https://www.who.int/groups/strategic-advisory-group-of-experts-on-immunization/covid-19-materials>
5. McGill COVID19 Vaccine Tracker Team. COVID-19 vaccine development and approvals tracker [Internet]. Montreal, QC: McGill University; 2020 [modified 2021 Jul 26; cited 2021 Jul 28]. Available from: <https://covid19.trackvaccines.org>

Citation

Ontario Agency for Health Protection and Promotion (Public Health Ontario). COVID-19 vaccine with World Health Organization (WHO) Emergency Use Listing (EUL). Toronto, ON: Queen's Printer for Ontario; 2021.

Disclaimer

This document was developed by Public Health Ontario (PHO). PHO provides scientific and technical advice to Ontario's government, public health organizations and health care providers. PHO's work is guided by the current best available evidence at the time of publication.

The application and use of this document is the responsibility of the user. PHO assumes no liability resulting from any such application or use.

This document may be reproduced without permission for non-commercial purposes only and provided that appropriate credit is given to PHO. No changes and/or modifications may be made to this document without express written permission from PHO.

Public Health Ontario

Public Health Ontario is an agency of the Government of Ontario dedicated to protecting and promoting the health of all Ontarians and reducing inequities in health. Public Health Ontario links public health practitioners, front-line health workers and researchers to the best scientific intelligence and knowledge from around the world.

For more information about PHO, visit publichealthontario.ca.

©Queen's Printer for Ontario, 2021

Ontario 